Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
18 results
D2.76 - Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria A Cross-Sectional Study from Kazakhstan
D2.77 - Lanadelumab in C1-Esterase Inhibitor Non-Responding patient: A Case Report
D2.83 - Management of Non IgE Cow's Milk Allergy: Current Practices and Challenges
D2.75 - Prevalence of Attention Deficit Hyperactivity Disorder and Related Factors in Children Aged 6-14 Years Diagnosed with Allergic Rhinitis
D2.78 - Comparative analysis of IgE reactivity to fish extracts versus beta-parvalbumin molecules in allergic patients
D2.82 - Analytical Performance Evaluation of Cor a 8, Cor a 9, and Cor a 14 Hazelnut Components on IMMULITE 2000 XPi*
D2.84 - Avoiding Mislabeling of Drug Allergy in Patients with Recurrent Cutaneous Symptoms
D2.85 - Analytical Performance Evaluation of Bet v 4 and Cor a 1 on IMMULITE 2000 XPi*
D2.86 - Nasal Nitric Oxide in Routine Practice: Results of a One-Year Clinical Experience in Pediatric Allergology
D2.89 - Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria?
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
Download the app
The congress at your fingertips
Available on
Download